How big is Seelos Therapeutics, Inc.?

As of December 2023, Seelos Therapeutics, Inc. has an unavailable market capitalization, reported net sales of 2.02 million, a net profit of 4.10 million, negative shareholder's funds of -33.51 million, and total assets of 5.42 million.

As of December 2023, Seelos Therapeutics, Inc. has a market capitalization value that is not available, making it difficult to categorize its market cap type.<BR><BR>As of December 2023, the company reported net sales of 2.02 million for the latest four quarters, alongside a net profit of 4.10 million for the same period.<BR><BR>As of December 2023, the company's shareholder's funds stood at -33.51 million, while total assets were reported at 5.42 million.

Should I buy, sell or hold Seelos Therapeutics, Inc.?

Who are in the management team of Seelos Therapeutics, Inc.?

As of March 2022, the management team of Seelos Therapeutics, Inc. includes Raj Mehra (Chairman, President, CEO, and Interim CFO) and board members Dr. Judith Dunn, Dr. Brian Lian, Daniel O'Connor, and Richard Pascoe.

As of March 2022, the management team of Seelos Therapeutics, Inc. includes Mr. Raj Mehra, who serves as the Chairman of the Board, President, Chief Executive Officer, and Interim Chief Financial Officer. Other members of the Board of Directors are Dr. Judith Dunn, Dr. Brian Lian, Mr. Daniel O'Connor, and Mr. Richard Pascoe.

Is Seelos Therapeutics, Inc. overvalued or undervalued?

As of April 15, 2025, Seelos Therapeutics, Inc. has been downgraded to "does not qualify" due to overvaluation and poor performance metrics, including a P/E ratio of 0.00 and a year-to-date return of -100%, making it an unviable investment compared to its peers and the S&P 500.

As of 15 April 2025, the valuation grade for Seelos Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company appears to be overvalued given its current metrics, particularly with a P/E ratio of 0.00 and an EV to EBITDA of -0.33, which suggests a lack of profitability and negative enterprise value relative to earnings. Additionally, the ROE stands at an exceptionally high 106.13%, but this is misleading due to the negative capital employed, further complicating the valuation picture.<BR><BR>In comparison to its peers, Seelos Therapeutics is underperforming, with Pieris Pharmaceuticals showing a P/E of -25.1964 and Coeptis Therapeutics at -4.6862, indicating that these companies are also struggling but at different levels. The stock has experienced a dramatic decline, with a year-to-date return of -100%, contrasting sharply with the S&P 500's positive return of 12.22% during the same period, reinforcing the notion that Seelos is not a viable investment at this time.

Is Seelos Therapeutics, Inc. technically bullish or bearish?

As of February 24, 2025, Seelos Therapeutics, Inc. shows a mildly bearish technical trend with mixed signals across indicators, and has underperformed the S&P 500 significantly, with a -100% return year-to-date and over the past year.

As of 24 February 2025, the technical trend for Seelos Therapeutics, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is also mildly bullish. However, the monthly RSI is bearish, and the daily moving averages are mildly bearish. The Bollinger Bands show a sideways trend on the weekly timeframe and a mildly bearish trend on the monthly timeframe. The KST is mildly bullish weekly but bearish monthly, and Dow Theory shows no trend in both weekly and monthly perspectives. <BR><BR>Overall, the technical stance is mildly bearish, with mixed signals across different indicators. Notably, the company has experienced a -100% return year-to-date and over the past year, significantly underperforming the S&P 500, which has returned 12.22% and 17.14% respectively.